Avacta (AVCT) is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology, which continues to dominate the drug industry, despite its limitations. The significant technical and commercial benefits of Affimers are being recognised increasingly through corporate and academic interest, on-going evaluations, and deal flow. A co-development partnership has been signed with Bach Biosciences (Tufts) for development of a new type of Affimer-drug conjugate (AfDC), that is already attracting attention from large pharma companies.
If you'd like to be introduced to the team at Avacta Group plc, get in touch.Request a meeting